Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Case report

Varenicline induced acute interstitial nephritis in the setting of idiopathic membranous glomerulonephritis

Authors: Wilson Kwong, Christine A White

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Varenicline is a nicotinic receptor partial agonist indicated for the cessation of smoking. It is regarded as having no or minimal renal toxicity. A single case report has linked it to acute interstitial nephritis.

Case presentation

A 56 year-old female with a long-standing history of idiopathic membranous glomerulonephritis presented on routine follow-up with an unexpected rise in her serum creatinine from a stable baseline of 225 umol/L to 319 umol/L Biopsy revealed acute interstitial nephritis. There were no preceding clinical events other than the initiation of varenicline therapy three months prior. This was discontinued with no improvement in renal function. A ten week course of prednisone was initiated and creatinine levels returned to baseline. Shortly after prednisone therapy was completed, renal function worsened but the patient declined further immunosuppressive therapy. Exposure to varenicline therapy two years prior had also resulted in a reversible decline in kidney function.

Conclusion

This is only the second case report to document varenicline-induced acute interstitial nephritis. A careful medication history and renal biopsy were essential in identifying the etiology of the acute kidney injury in this patient with a complex renal history.
Appendix
Available only for authorised users
Literature
1.
go back to reference Polosa R, Benowitz NL: Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci. 2011, 32: 281-9. 10.1016/j.tips.2010.12.008.CrossRefPubMed Polosa R, Benowitz NL: Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci. 2011, 32: 281-9. 10.1016/j.tips.2010.12.008.CrossRefPubMed
2.
go back to reference Burstein AH, Fullerton T, Clark DJ, Faessel HM: Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol. 2006, 46: 1234-40. 10.1177/0091270006291837.CrossRefPubMed Burstein AH, Fullerton T, Clark DJ, Faessel HM: Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol. 2006, 46: 1234-40. 10.1177/0091270006291837.CrossRefPubMed
3.
go back to reference Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM: Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol. 2009, 68: 669-81. 10.1111/j.1365-2125.2009.03520.x.CrossRefPubMedPubMedCentral Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM: Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol. 2009, 68: 669-81. 10.1111/j.1365-2125.2009.03520.x.CrossRefPubMedPubMedCentral
4.
go back to reference Zhao Q, Schwam E, Fullerton T, et al: Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers. J Clin Pharmacol. 2011, 51: 492-501. 10.1177/0091270010370461.CrossRefPubMed Zhao Q, Schwam E, Fullerton T, et al: Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers. J Clin Pharmacol. 2011, 51: 492-501. 10.1177/0091270010370461.CrossRefPubMed
5.
go back to reference Pfizer Canada Inc. Product Monograph CHAMPIX: Varenicline tartrate. 2011 Pfizer Canada Inc. Product Monograph CHAMPIX: Varenicline tartrate. 2011
6.
go back to reference Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011, 183: 1359-66. 10.1503/cmaj.110218.CrossRefPubMedPubMedCentral Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011, 183: 1359-66. 10.1503/cmaj.110218.CrossRefPubMedPubMedCentral
7.
go back to reference Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR: Varenicline phase 3 study group: varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 47-55. 10.1001/jama.296.1.47.CrossRefPubMed Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR: Varenicline phase 3 study group: varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 47-55. 10.1001/jama.296.1.47.CrossRefPubMed
8.
go back to reference Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR: Varenicline phase 3 study group: efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 56-63. 10.1001/jama.296.1.56.CrossRefPubMed Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR: Varenicline phase 3 study group: efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 56-63. 10.1001/jama.296.1.56.CrossRefPubMed
9.
go back to reference Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR: Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006, 166: 1561-8. 10.1001/archinte.166.15.1561.CrossRefPubMed Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR: Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006, 166: 1561-8. 10.1001/archinte.166.15.1561.CrossRefPubMed
10.
go back to reference Bird ML, Vesta KS: Varenicline-associated acute renal failure. Ann Pharmacother. 2008, 42: 1908-11. 10.1345/aph.1L355.CrossRefPubMed Bird ML, Vesta KS: Varenicline-associated acute renal failure. Ann Pharmacother. 2008, 42: 1908-11. 10.1345/aph.1L355.CrossRefPubMed
11.
go back to reference Selby MG, Fidler ME, Shields RC, Kashani KB: Does varenicline induce acute interstitial nephritis. Mayo Clin Proc. 84: 560-1. Selby MG, Fidler ME, Shields RC, Kashani KB: Does varenicline induce acute interstitial nephritis. Mayo Clin Proc. 84: 560-1.
12.
go back to reference Haas M, Spargo BH, Wit EJ, Meehan SM: Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis. 2000, 35: 433-47. 10.1016/S0272-6386(00)70196-X.CrossRefPubMed Haas M, Spargo BH, Wit EJ, Meehan SM: Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis. 2000, 35: 433-47. 10.1016/S0272-6386(00)70196-X.CrossRefPubMed
13.
go back to reference Praga M, Gonzalez E: Acute interstitial nephritis. Kidney Int. 2010, 77: 956-61. 10.1038/ki.2010.89.CrossRefPubMed Praga M, Gonzalez E: Acute interstitial nephritis. Kidney Int. 2010, 77: 956-61. 10.1038/ki.2010.89.CrossRefPubMed
14.
go back to reference Baker RJ, Pusey CD: The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2004, 19: 8-11. 10.1093/ndt/gfg464.CrossRefPubMed Baker RJ, Pusey CD: The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2004, 19: 8-11. 10.1093/ndt/gfg464.CrossRefPubMed
15.
go back to reference Perazella MA, Markowitz GS: Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010, 6: 461-70. 10.1038/nrneph.2010.71.CrossRefPubMed Perazella MA, Markowitz GS: Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010, 6: 461-70. 10.1038/nrneph.2010.71.CrossRefPubMed
16.
go back to reference Rossert J: Drug-induced acute interstitial nephritis. Kidney Int. 2001, 60: 804-17. 10.1046/j.1523-1755.2001.060002804.x.CrossRefPubMed Rossert J: Drug-induced acute interstitial nephritis. Kidney Int. 2001, 60: 804-17. 10.1046/j.1523-1755.2001.060002804.x.CrossRefPubMed
17.
go back to reference Buysen JG, Houthoff HJ, Krediet RT, Arisz L: Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant. 1990, 5: 94-9. 10.1093/ndt/5.2.94.CrossRefPubMed Buysen JG, Houthoff HJ, Krediet RT, Arisz L: Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant. 1990, 5: 94-9. 10.1093/ndt/5.2.94.CrossRefPubMed
18.
go back to reference Gonzalez E, Gutierrez E, Galeano C, Chevia C, De Sequera P, Bernis C, Parra EG, Delgado R, Sanz M, Ortiz M, Goicoechea M, Quereda C, Olea T, Bouarich H, Hernandez Y, Segovia B, Praga M, Grupo Madrileno De Nefritis Intersticiales: Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008, 73: 940-6. 10.1038/sj.ki.5002776.CrossRefPubMed Gonzalez E, Gutierrez E, Galeano C, Chevia C, De Sequera P, Bernis C, Parra EG, Delgado R, Sanz M, Ortiz M, Goicoechea M, Quereda C, Olea T, Bouarich H, Hernandez Y, Segovia B, Praga M, Grupo Madrileno De Nefritis Intersticiales: Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008, 73: 940-6. 10.1038/sj.ki.5002776.CrossRefPubMed
19.
go back to reference Clarkson MR, Giblin L, O'Connell FP, O'Kelly P, Walshe JJ, Conlon P, O'Meara Y, Dormon A, Campbell E, Donohoe J: Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004, 19: 2778-83. 10.1093/ndt/gfh485.CrossRefPubMed Clarkson MR, Giblin L, O'Connell FP, O'Kelly P, Walshe JJ, Conlon P, O'Meara Y, Dormon A, Campbell E, Donohoe J: Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004, 19: 2778-83. 10.1093/ndt/gfh485.CrossRefPubMed
20.
go back to reference Preddie DC, Markowitz GS, Radhakrishnan J, Nickolas TL, D'Agati VD, Schwimmer JA, Gardenswartz M, Rosen R, Appel GB: Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol. 2006, 1: 718-22. 10.2215/CJN.01711105.CrossRefPubMed Preddie DC, Markowitz GS, Radhakrishnan J, Nickolas TL, D'Agati VD, Schwimmer JA, Gardenswartz M, Rosen R, Appel GB: Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol. 2006, 1: 718-22. 10.2215/CJN.01711105.CrossRefPubMed
Metadata
Title
Varenicline induced acute interstitial nephritis in the setting of idiopathic membranous glomerulonephritis
Authors
Wilson Kwong
Christine A White
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-248

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.